A new publication supports Diamyd Medical’s patent rights around GABA

A new scientific article published in Journal of Diabetes Research supports previous findings that form the basis of patent applications that Diamyd Medical exclusively licenses from University of California, Los Angeles (UCLA). The study shows that treatment with GABA in combination with the GABA receptor modulating agent Alprazolam provides increased effect on the survival and growth of insulin-producing cells in animals.The authors behind the publication, active at UCLA, have investigated the influence of GABA and the GABA receptor modulator Alprazolam on diabetic mice transplanted with